PMID- 37705735
OWN - NLM
STAT- MEDLINE
DCOM- 20230915
LR  - 20230919
IS  - 1449-2288 (Electronic)
IS  - 1449-2288 (Linking)
VI  - 19
IP  - 13
DP  - 2023
TI  - Seeing the T cell Immunity of SARS-CoV-2 and SARS-CoV: Believing the 
      Epitope-Oriented Vaccines.
PG  - 4052-4060
LID - 10.7150/ijbs.80468 [doi]
AB  - The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at 
      the end of 2019 stimulated vigorous research efforts in immunology and 
      vaccinology. In addition to innate immune responses, both virus-specific humoral 
      and cellular immune responses are of importance for viral clearance. T cell 
      epitopes play a central role in T cell-based immune responses. Herein, we 
      summarized the peptide/major histocompatibility complex (pMHC) structures of the 
      SARS-CoV-2-derived T cell epitopes available in the Protein Data Bank (PDB) and 
      proposed the challenge and opportunities for using of T cell epitopes in future 
      vaccine development efforts. A total of 27 SARS-CoV-2 related pMHC structures and 
      five complexes with T cell receptors were retrieved. The peptides are mainly 
      distributed on spike (S), nucleocapsid (N), and ORF1ab proteins. Most peptides 
      are conserved among variants of concerns (VOCs) for SARS-CoV-2, except for 
      several mutated peptides located in the S protein. The structures of human 
      leukocyte antigen (HLA) complexed with seven epitopes derived from SARS-CoV were 
      also retrieved, which showed a potential cross T cell immunity with SARS-CoV-2. 
      Structural studies of antigenic peptides from SARS-CoV-2 and SARS-CoV help to 
      visualize the processes and the mechanisms of cross T cell immunity. T cell 
      epitope-oriented vaccines are potential next-generation vaccines for SARS-CoV-2, 
      which are worthy of further investigation.
CI  - (c) The author(s).
FAU - Yue, Can
AU  - Yue C
AD  - CAS Key Laboratory of Infection and Immunity, National Laboratory of 
      Macromolecules, Institute of Biophysics, Chinese Academy of Sciences (CAS), 
      Beijing, China.
FAU - Wang, Pengyan
AU  - Wang P
AD  - Department of Pathogen Biology & Microbiology, School of Medicine, Zhejiang 
      University, Hangzhou, Zhejiang, China.
FAU - Tian, Jinmin
AU  - Tian J
AD  - NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and 
      Prevention, Chinese Center for Disease Control and Prevention (China CDC), 
      Beijing, China.
AD  - School of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical University, 
      Wenzhou, Zhejiang, China.
FAU - Gao, George F
AU  - Gao GF
AD  - NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and 
      Prevention, Chinese Center for Disease Control and Prevention (China CDC), 
      Beijing, China.
AD  - CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of 
      Microbiology, Chinese Academy of Sciences (CAS), Beijing, China.
FAU - Liu, Kefang
AU  - Liu K
AD  - CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of 
      Microbiology, Chinese Academy of Sciences (CAS), Beijing, China.
AD  - Shenzhen Children's Hospital, Shenzhen, Guangdong, China.
FAU - Liu, William J
AU  - Liu WJ
AD  - NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and 
      Prevention, Chinese Center for Disease Control and Prevention (China CDC), 
      Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20230806
PL  - Australia
TA  - Int J Biol Sci
JT  - International journal of biological sciences
JID - 101235568
RN  - 0 (Epitopes, T-Lymphocyte)
RN  - 0 (COVID-19 Vaccines)
SB  - IM
MH  - Humans
MH  - *T-Lymphocytes
MH  - Epitopes, T-Lymphocyte
MH  - SARS-CoV-2
MH  - COVID-19 Vaccines
MH  - *COVID-19/prevention & control
PMC - PMC10496500
OTO - NOTNLM
OT  - COVID-19
OT  - Epitope
OT  - SARS-CoV-2
OT  - Sarbecoviruses
OT  - TCR
OT  - Vaccine
OT  - pMHC
COIS- Competing Interests: The authors have declared that no competing interest exists.
EDAT- 2023/09/14 06:42
MHDA- 2023/09/15 06:42
PMCR- 2023/01/01
CRDT- 2023/09/14 04:06
PHST- 2022/11/03 00:00 [received]
PHST- 2023/07/07 00:00 [accepted]
PHST- 2023/09/15 06:42 [medline]
PHST- 2023/09/14 06:42 [pubmed]
PHST- 2023/09/14 04:06 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - ijbsv19p4052 [pii]
AID - 10.7150/ijbs.80468 [doi]
PST - epublish
SO  - Int J Biol Sci. 2023 Aug 6;19(13):4052-4060. doi: 10.7150/ijbs.80468. eCollection 
      2023.